Alzheimer's Disease (AD) is a brain condition that affects memory and thinking. This study is testing a new medicine called AR1001 to see if it helps people with early AD feel better and is safe. It's a Phase 3 trial, which means the medicine has already been tested in earlier trials. Some participants will get AR1001, and others will get a placebo (a fake treatment) to compare the results. This is called a double-blind study, meaning neither the participants nor the doctors know who gets the real medicine.

• The study lasts several months and requires multiple clinic visits.
• Participants must be 55-90 years old with early AD symptoms.
• Participants and their study partners need to sign consent forms.

To join, you need to meet specific health requirements, like having certain scores on memory tests and being free of other major health issues. This study will help doctors understand if AR1001 can be a new treatment for Alzheimer's Disease.